Clinical Trial Update: Sintilimab (IBI308) in the Neoadjuvant Treatment of Patients With Resectable II-IIIA NSCLC [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating sintilimab (IBI308) as neoadjuvant therapy for resectable stage II-IIIA non-small cell lung cancer, with status currently un…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Sintilimab (sintilimab)

Snippet

Sponsor: Sichuan Cancer Hospital and Research Institute | Conditions: Lung Diseases, Neoplasms | Phase 2 | Status: UNKNOWN